Sharp Therapeutics Corp. (SHRXF)
| Market Cap | 49.76M |
| Revenue (ttm) | n/a |
| Net Income | -3.33M |
| EPS | -0.11 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 4,656 |
| Open | 1.660 |
| Previous Close | 1.660 |
| Day's Range | 1.660 - 1.660 |
| 52-Week Range | 0.304 - 3.460 |
| Beta | n/a |
| RSI | 42.30 |
| Earnings Date | Apr 24, 2026 |
About Sharp Therapeutics
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania. [Read more]
Financial Performance
Financial StatementsNews
Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has cl...
Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has...
Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms of...
Sharp Therapeutics Appoints Co-Founder Of National Gaucher Foundation And Clinical Researcher Robin Ely, M.D., To Advisory Board
PITTSBURGH and TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Sharp Therapeutics Corp. ("Sharp" or the "Company") (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule therapeuti...
Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that the n...
Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its cond...
Sharp Therapeutics Arranges Non-Brokered Private Placement
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that it is ...
Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025
PITTSBURGH, Pa. and TORONTO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Sharp Therapeutics Corp. ("Sharp" or the "Company") (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule thera...
Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its condens...